Ironwood Pharmaceuticals, Inc. - Class A (IRWD)
Ironwood Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and other specialty health conditions. Known for its expertise in microbiome and gastrointestinal biology, Ironwood's portfolio includes products and pipelines aimed at improving patient outcomes through innovative treatments.
Company News
Ironwood Pharmaceuticals' stock plunged after the FDA requested a confirmatory Phase 3 trial for its gastrointestinal drug apraglutide, despite strong data from the initial trial.
Beam Therapeutics, a biotechnology company developing precision genetic medicines, has appointed Sravan K. Emany as its new Chief Financial Officer. Emany brings extensive experience in the life sciences industry and will help guide Beam's growth and capital allocation strategy.
Three stocks were added to the Zacks Rank #5 (Strong Sell) list today: Arcos Dorados Holdings Inc., Ironwood Pharmaceuticals, Inc., and Avnet, Inc. The Zacks Consensus Estimate for their current year earnings has been revised downward over the last 60 days.
A more selective small-cap index has consistently outperformed the Russell 2000
Ironwood's plan to purchase a smaller biotech should address some issues that have shareholders concerned.
